- Home
- MLYS vs ARCT Comparison
MLYS vs ARCT Comparison
Compare MLYS & ARCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MLYS
- ARCT
- Stock Information
- Founded
- MLYS 2019
- ARCT 2013
- Country
- MLYS United States
- ARCT United States
- Employees
- MLYS N/A
- ARCT N/A
- Industry
- MLYS Biotechnology: Pharmaceutical Preparations
- ARCT Biotechnology: Pharmaceutical Preparations
- Sector
- MLYS Health Care
- ARCT Health Care
- Exchange
- MLYS Nasdaq
- ARCT Nasdaq
- Market Cap
- MLYS 890.6M
- ARCT 320.8M
- IPO Year
- MLYS 2023
- ARCT N/A
- Fundamental
- Price
- MLYS $37.29
- ARCT $18.05
- Analyst Decision
- MLYS Strong Buy
- ARCT Strong Buy
- Analyst Count
- MLYS 6
- ARCT 10
- Target Price
- MLYS $42.60
- ARCT $50.88
- AVG Volume (30 Days)
- MLYS 2.6M
- ARCT 493.8K
- Earning Date
- MLYS 11-10-2025
- ARCT 11-06-2025
- Dividend Yield
- MLYS N/A
- ARCT N/A
- EPS Growth
- MLYS N/A
- ARCT N/A
- EPS
- MLYS N/A
- ARCT N/A
- Revenue
- MLYS N/A
- ARCT $122,122,000.00
- Revenue This Year
- MLYS N/A
- ARCT N/A
- Revenue Next Year
- MLYS N/A
- ARCT $28.92
- P/E Ratio
- MLYS N/A
- ARCT N/A
- Revenue Growth
- MLYS N/A
- ARCT N/A
- 52 Week Low
- MLYS $8.24
- ARCT $8.04
- 52 Week High
- MLYS $39.20
- ARCT $25.88
- Technical
- Relative Strength Index (RSI)
- MLYS 82.81
- ARCT 58.87
- Support Level
- MLYS $34.59
- ARCT $16.54
- Resistance Level
- MLYS $39.20
- ARCT $19.50
- Average True Range (ATR)
- MLYS 2.83
- ARCT 1.08
- MACD
- MLYS 0.73
- ARCT -0.08
- Stochastic Oscillator
- MLYS 92.13
- ARCT 56.46
About MLYS Mineralys Therapeutics Inc.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.
About ARCT Arcturus Therapeutics Holdings Inc.
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on opportunities in rare diseases with a current focus on liver and respiratory diseases. It operates in one business segment, which includes all activities related to the discovery, development and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC, LUNAR-CF, LUNAR-FLU, and LUNAR-COV19.